Market Place
Sourcing Support
All News #Library
Biotech
Radiopharm Theranostics Reports Business Update
23 Apr 2026 //
GLOBENEWSWIRE
Radiopharm Theranostics Initiates RAD 402 Phase 1 Trial
27 Mar 2026 //
GLOBENEWSWIRE
Radiopharm Meets Primary Endpoint in 90% of RAD-101 Patients
24 Mar 2026 //
GLOBENEWSWIRE
Radiopharm Starts Phase 1/2A Trial of Betabart (RV-01)
24 Feb 2026 //
GLOBENEWSWIRE
RAD Increases Ownership In Radiopharm Ventures To 87.5%
12 Jan 2026 //
GLOBENEWSWIRE
Radiopharm Theranostics Begins Phase 1 Trial For RAD 402
18 Nov 2025 //
GLOBENEWSWIRE
Radiopharm Hits 50% Enrollment in Ph2b RAD101 Brain Met Trial
17 Nov 2025 //
GLOBENEWSWIRE
Radiopharm Starts Enrollment of Third Cohort of 177 Lu-Rad204
12 Nov 2025 //
GLOBENEWSWIRE
Radiopharm Theranostics Reports Positive Clinical Progress
20 Oct 2025 //
GLOBENEWSWIRE
Radiopharm Theranostics Gets Dsmc Nod To Fast-Track 177LU-RAD202
01 Oct 2025 //
GLOBENEWSWIRE
Radiopharm Gets FDA Nod for Ph1 B7H3-Targeting Study
28 Jul 2025 //
GLOBENEWSWIRE
Radiopharm and Cyclotek Ink Deal for 161Tb KLK3 Ph 1 Trial
24 Jun 2025 //
GLOBENEWSWIRE
ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177
19 May 2025 //
GLOBENEWSWIRE
RAD202 Data Confirms Positive Tumor Uptake
17 Mar 2025 //
GLOBENEWSWIRE
RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody
09 Oct 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.